Calan 40mg is an oral and parenteral calcium-channel blocking (CCB) agent. Calan 40mg (HCT) is useful for the treatment of angina, hypertension, and for supraventricular tachyarrhythmias. Calan 40mg is considered a class IV antiarrhythmic agent and Calan 40mg (HCI) is more effective than digoxin for controlling ventricular rate in patients with atrial fibrillation. Calan 40mg was synthesized in 1962 and, in 1981, became the first calcium channel blocker to be approved by the FDA Calan 40mg inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. It exerts its activity at the membrane surface of arterial smooth muscle cells and within conductile and contractile tissue in the myocardium, but the serum calcium levels remain unchanged.
Calan 40mg (HCI) is primarily indicated in conditions like Angina, Cardiac arrhythmia, Hypertension, ischaemic heart disease, Paroxysmaltachyarrhythmias, Supraventricular arrhythmias, Supraventricular tachycardia, and can also be given in adjunctive therapy as an alternative drug of choice in Cardiomyopathy, Migraine Psychosis, Pulmonary hypertension
Calan 40mg (HCI) is contraindicated in conditions like Heart failure,Bradycardia Platelet dysfunction.
The severe or irreversible adverse effects of Calan 40mg (HCI), which give rise to further complications include Hepatotoxicity, Impotence, Mental confusion, Hyperprolactinemia, Myoclonic dystonia Calan 40mg (HCI) produces potentially life-threatening effects which include Cardiac arrhythmias, Heart failure, which are responsible for the discontinuation of Calan 40mg (HCI) therapy. The signs and symptoms that are produced after the acute overdosage of Calan 40mg (HCN) include Bradycardia, Hypotension, AV block. The symptomatic adverse reactions produced by Calan 40mg (HCI) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Fatigue, Nausea, Palpitation, Constipation, Flushing
Calan 40mg should be used with caution in patients with liver or kidney impairment. Consider decrease in dose of calcium channel blockers and monitor drug response in cirrhosis patients
High Risk Groups
Drug should not be given to patients suffering from Liver Malfunction. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies